Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 33Gastrointestinal 14Genitourinary 11Thoracic 7Breast 6Sarcoma 5Dermatologic 5CNS 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Other solid neoplasm 1Head & Neck 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma 23Burkitt Lymphoma 22Multiple Myeloma 20Lymphoma, Non-Hodgkin 17Leukemia, Myeloid, Acute 16Lymphoma, Follicular 15Myelodysplastic Syndromes 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 13Leukemia, Biphenotypic, Acute 13Lymphoma, T-Cell 9Hodgkin Disease 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Wilms Tumor 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Central Nervous System Neoplasms 6Rhabdoid Tumor 5Primary Myelofibrosis 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Myeloproliferative Disorders 5Mycosis Fungoides 5

Interventions

pembrolizumab 6Paclitaxel 4Cyclophosphamide 4Psychiatric Rehabilitation 3Flow Cytometry 3Filgrastim 3Drug Therapy 3Carboplatin 3valspodar 2trametinib 2sargramostim 2epacadostat 2dabrafenib 2X-Rays 2Specimen Handling 2Nivolumab 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Injections 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Dasatinib 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Specimen Handling × Lymphoid × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡